Lyme Disease Vaccine Moves to Phase III as Booster Trial Proves Effective

The Phase II trial, VLA150202, evaluated the safety and immunogenicity of VLA15 on 246 healthy adults aged 18 to 65 years old across the United States.

Related Keywords

France ,United States ,French ,Americans ,Kathrin Jansen ,Pfizer ,Pfizer Vaccine Research ,Ospa Igg ,Northern Hemisphere ,Fast Track ,Drug Administration ,Resume ,Careers ,Yme Disease Vaccine Moves To Phase Iii As Booster Trial Proves Effective ,Iospace ,Advice ,